Pharmaceutical

Risk adjusted net present value: What is the current valuation of AbbVie’s ABBV-400?

ABBV-400 is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Metastatic Colorectal Cancer.

Apr 17, 2024 - 00:00
ABBV-400 is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Metastatic Colorectal Cancer.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Merck’s MK-1084?

Next Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Biosyngen receives FDA approval to start Phase I trial for TCR therapy

Biosyngen receives FDA approval to start Phase I trial ...

Sep 11, 2023

House Republicans demand career scientist explain pathogen research

House Republicans demand career scientist explain patho...

May 31, 2023

‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs

‘Robbing Peter to pay Paul’: Obesity experts debate ris...

May 9, 2023